Abstract:Background: Type 1 diabetes (T1D) is a devastating autoimmune disease, and its rising prevalence in the United States and around the world presents a critical problem in public health. While some treatment options exist for patients already diagnosed, individuals considered at risk for developing T1D and who are still in the early stages of their disease pathogenesis without symptoms have no options for any preventive intervention. This is because of the uncertainty in determining their risk level and in predicting with high confidence who will progress, or not, to clinical diagnosis. Biomarkers that assess one's risk with high certainty could address this problem and will inform decisions on early intervention, especially in children where the burden of justifying treatment is high. Single omics approaches (e.g., genomics, proteomics, metabolomics, etc.) have been applied to identify T1D biomarkers based on specific disturbances in association with the disease. However, reliable early biomarkers of T1D have remained elusive to date. To overcome this, we previously showed that parallel multi-omics provides a more comprehensive picture of the disease-associated disturbances and facilitates the identification of candidate T1D biomarkers. Methods: This paper evaluated the use of machine learning (ML) using data augmentation and supervised ML methods for the purpose of improving the identification of salient patterns in the data and the ultimate extraction of novel biomarker candidates in integrated parallel multi-omics datasets from a limited number of samples. We also examined different stages of data integration (early, intermediate, and late) to assess at which stage supervised parametric models can learn under conditions of high dimensionality and variation in feature counts across different omics. In the late integration scheme, we employed a multi-view ensemble comprising individual parametric models trained over single omics to address the computational challenges posed by the high dimensionality and variation in feature counts across the different yet integrated multi-omics datasets. Results: the multi-view ensemble improves the prediction of case vs. control and finds the most success in flagging a larger consistent set of associated features when compared with chance models, which may eventually be used downstream in identifying a novel composite biomarker signature of T1D risk. Conclusions: the current work demonstrates the utility of supervised ML in exploring integrated parallel multi-omics data in the ongoing quest for early T1D biomarkers, reinforcing the hope for identifying novel composite biomarker signatures of T1D risk via ML and ultimately informing early treatment decisions in the face of the escalating global incidence of this debilitating disease.

Exploring Biomarker Relationships in Both Type 1 and Type 2 Diabetes Mellitus Through a Bayesian Network Analysis Approach

Bayesian network analysis of factors influencing type 2 diabetes, coronary heart disease, and their comorbidities

Integrating Bayesian Approaches and Expert Knowledge for Forecasting Continuous Glucose Monitoring Values in Type 2 Diabetes Mellitus

Machine Learning as a Support for the Diagnosis of Type 2 Diabetes

Pilot-Study to Explore Metabolic Signature of Type 2 Diabetes: A Pipeline of Tree-Based Machine Learning and Bioinformatics Techniques for Biomarkers Discovery

A patient network-based machine learning model for disease prediction: The case of type 2 diabetes mellitus

Research on Potential Network Markers and Signaling Pathways in Type 2 Diabetes Based on Conditional Cell-Specific Network

Metabolomics and correlation network analyses of core biomarkers in type 2 diabetes

Detecting early-warning signals of type 1 diabetes and its leading biomolecular networks by dynamical network biomarkers

Detecting tissue-specific early warning signals for complex diseases based on dynamical network biomarkers: study of type 2 diabetes by cross-tissue analysis

Supervised Parametric Learning in the Identification of Composite Biomarker Signatures of Type 1 Diabetes in Integrated Parallel Multi-Omics Datasets

Systems Approach to Pathogenic Mechanism of Type 2 Diabetes and Drug Discovery Design Based on Deep Learning and Drug Design Specifications

Metabolomics-based Multidimensional Network Biomarkers for Diabetic Retinopathy Identification in Patients with Type 2 Diabetes Mellitus

A Three-gene-based Type 1 Diabetes Diagnostic Signature

Machine-learning to stratify diabetic patients using novel cardiac biomarkers and integrative genomics

Investigating the Impact of Multiple Inputs on Predicting Glucose Level in Individuals with Type-1 Diabetes through Deep Learning Technique

AI-driven Integration of Multimodal Imaging Pixel Data and Genome-wide Genotype Data Enhances Precision Health for Type 2 Diabetes: Insights from a Large-scale Biobank Study

Machine Learning Reveals Metabolic Signatures in Patients with Type 1 Diabetes

The classical Biomarkers to Predict Diabetes Mellitus

Integrative Network Analysis Unveils Convergent Molecular Pathways in Parkinson's Disease and Diabetes

Metabolomics in human type 2 diabetes research